Robert Haddad
McGraw Chair in Head and Neck Oncology · Mass General Brigham
Credentials: · · ·
History
- Present
- Present
head and neck oncology at Dana-Farber, and Division · Mass General Brigham
- Present
Division of Head and Neck Oncology · Mass General Brigham
- 1995–1998
Roosevelt Hospital Center
- 1991–1995
Saint Joseph University Medical School
Research
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
New England Journal of Medicine · 2016 · 4,100 citations
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
New England Journal of Medicine · 2007 · 1,268 citations
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 1,128 citations
82 papers
- MP
73 papers
55 papers · 2 as a resident
50 papers
- GH
49 papers · 7 as a resident
44 papers
- LW
42 papers · 6 as a fellow
38 papers
Grants
- 2019–2024
Defining Mechanisms of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinomas
National Institute of Dental and Craniofacial Research · U01
PI · $4.3M · Dana-Farber Cancer Inst
Clinical trials
- 2019–2022
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
- 2015–2017
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Principal investigator · Completed · Phase 1, Phase 2
Dana-Farber Cancer Institute
- 2014–2016
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
- 2011–2017
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute